Clearbridge BioMedics raises USD7.2M Series B from Vertex Venture, others
March 13, 2013 by Terence LEE
Clearbridge BioMedics, Singapore-based medical tech company, has today announced a new series B venture round of SGD 9M (USD 7.2M). Vertex Venture Holdings, a wholly owned venture capital arm of Temasek Holdings, is the lead investor.
The startup’s flagship product is the ClearCell System, which consists of patent-pending CTChips that are able to detect, isolate, and retrieve tumor cells from blood samples obtained from patients. The isolated tumor cells can then be stained for identification and analysis.
The technology, which has applications in cancer screening, diagnosis, medication, and treatment monitoring, is designed to be a form of non-invasive liquid biopsy — or medical test. The company already has customers in Asia, Europe, and North America.
Other investors in this round includes government co-funding scheme SPRING Seeds Capital, Clearbridge BSA, Biosensors International founder Lu Yoh Chie, and existing shareholder BioVeda.
Lu will also join Clearbridge BioMedics’ board of directors.
Visit VentureDex for more information about funding options for startups in Asia.
Find out more about SGE’s research arm: SGE Insights, providing customized in-depth research reports to help you navigate the business of technology in Asia.
About The Author
Terence LEE - Editor
Terence writes mainly about technology trends and startups in Asia. He believes in crafting smart content: Not just a regurgitation of text, but well thought-out pieces that serve the reader using a combination of data, design, narratives, analysis, and visual impact. His articles have been published on Venturebeat, Yahoo!, Straits Times, Today, and The Online Citizen. He also co-founded NewNation.sg, a satirical news site covering Singapore affairs. Engage him on LinkedIn and Twitter.
Read other posts by Terence LEE
Share this: